-
公开(公告)号:WO2015153513A1
公开(公告)日:2015-10-08
申请号:PCT/US2015/023432
申请日:2015-03-30
发明人: DU, Changchun , KIM, Jeong , ZHU, Jing , BEVERS, Jack , WALSH, Kevin , DE ALMEIDA, Patricia , ANDYA, James , SHEN, Ye
IPC分类号: C07K16/28
CPC分类号: C07K16/2878 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/70 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The disclosure provides anti-OX40 antibodies and methods of using the same.
摘要翻译: 本公开提供了抗OX40抗体及其使用方法。
-
2.COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS 审中-公开
标题翻译: 包含抗血管发生剂和OX40结合激素的联合治疗公开(公告)号:WO2015153514A1
公开(公告)日:2015-10-08
申请号:PCT/US2015/023434
申请日:2015-03-30
发明人: WALSH, Kevin , DE ALMEIDA, Patricia , DU, Changchun , KIM, Jeong , ZHU, Jing , BEVERS, Jack , ANDYA, James , SHEN, Ye
IPC分类号: C07K16/22 , C07K16/28 , A61P35/00 , A61K39/395
CPC分类号: C07K16/2878 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K48/00 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要: The disclosure provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.
摘要翻译: 本公开提供了治疗癌症的组合物和方法。 该方法包括施用抗血管生成剂和OX40结合激动剂。
-
公开(公告)号:WO2006044908A2
公开(公告)日:2006-04-27
申请号:PCT/US2005/037471
申请日:2005-10-19
申请人: GENENTECH, INC. , ANDYA, James, D. , GWEE, Shiang, C. , LIU, Jun , SHEN, Ye
发明人: ANDYA, James, D. , GWEE, Shiang, C. , LIU, Jun , SHEN, Ye
CPC分类号: A61K47/22 , A61K39/39541 , A61K39/39558 , A61K39/39591 , A61K47/26 , A61K2039/505 , C07K16/2878 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/94
摘要: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
摘要翻译: 本申请描述了抗体制剂,包括在组氨酸 - 乙酸盐缓冲液中配制的单克隆抗体,以及包含结合HER2结构域II(例如,Pertuzumab)的抗体的制剂和包含与DR5结合的抗体的制剂 例如,Apomab)。
-
-